natgillin/translations-raw huggingface dataset:
increase the tendency for blood clotting, decreased number of red blood cells, known as anaemia, or higher levels of certain types of white blood cells),
lahko povečajo nagnjenje krvi k strjevanju, zmanjšano število rdečih krvnih celic, kar imenujemo slabokrvnost; zvišane koncentracije nekaterih vrst belih krvnih celic),
- Decreased appetite,
- zmanjšan apetit,
- Dizziness, anxiety, difficulty in sleeping, tingling or numbness of the hands or feet, taste
- vrtoglavost, anksioznost, težave s spanjem, mravljinčenje ali odrevenelost dlani ali stopal,
disturbance,
motnje okušanja,
- Changes in heart rhythm, flushes, high or low blood pressure,
- spremembe srčnega ritma, navali rdečice, visok ali nizek krvni tlak,
- Constipation, abdominal pain, indigestion, inflammation of the tongue,
- zaprtje, bolečine v trebuhu, prebavne težave, vnetje jezika,
- Yellowing of the skin and eyes,
- porumenitev kože in oči,
- Itchy rash of skin,
- srbeč kožni izpuščaj,
- Muscle pain or weakness, joint pain,
- bolečine v mišicah ali šibkost mišic, bolečine v sklepih,
- kidney problems,
- težave z ledvicami,
- Inflammation and irritation of the vagina,
- vnetje in draženje v nožnici,
- General pain or weakness, fever, tiredness,
- bolečine po celem telesu ali šibkost, povišana telesna temperatura, utrujenost,
- Blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactic
- izvidi preiskav krvi, ki kažejo zvišane vrednosti glukoze v krvi, kreatinina v serumu,
dehydrogenase (LDH), or imbalance of salts.
mioglobina ali laktat- dehidrogenaze (LDH) ali elektrolitsko neravnovesje.
HOW TO STORE CUBICIN
SHRANJEVANJE ZDRAVILA CUBICIN
Your doctor, nurse or pharmacist knows how to store Cubicin properly.
Vaš zdravnik, medicinska sestra in farmacevt vedo, kako je treba pravilno shranjevati zdravilo Cubicin.
What Cubicin contains
Kaj vsebuje zdravilo Cubicin
- The active substance is daptomycin.
- Zdravilna učinkovina je daptomicin.
- The other ingredient is sodium hydroxide.
- Pomožna snov je natrijev hidroklorid.
What Cubicin looks like and contents of the pack Cubicin is supplied as a pale yellow to light brown powder in a glass vial.
Izgled zdravila Cubicin in vsebina pakiranja Zdravilo Cubicin je na voljo v obliki bledo rumenega do svetlo rjavega praška v stekleni viali.
Cubicin is available in packs containing 1 vial.
Zdravilo Cubicin je na voljo v pakiranjih, ki vsebujejo po 1 vialo.
Manufacturer Novartis Pharmaceuticals UK Limited Wimblehurst Road Horsham West Sussex, RH12 5AB United Kingdom
Izdelovalec Novartis Pharmaceuticals UK Limited Wimblehurst Road Horsham West Sussex, RH12 5AB Velika Britanija
43 INFORMATION FOR THE HEALTHCARE PROFESSIONALS
41 INFORMACIJE ZA ZDRAVSTVENE DELAVCE
Please refer to the Summary of Product Characteristics before prescribing.
Preden zdravilo predpišete, upoštevajte Povzetek glavnih značilnosti zdravila.
350 mg presentation: a 50 mg/ ml concentration can be achieved by reconstituting with 7 ml of 0.9% sodium chloride intravenous infusion.
Pakiranje po 350 mg: koncentracijo 50 mg/ ml lahko dosežete z rekonstitucijo s 7 ml 0, 9% natrijevega klorida za intravensko infuzijo.
Vials of 350 mg/ vial can also be reconstituted with sterile water for injections.
Viale s 350 mg/ vialo se lahko rekonstituirajo tudi s sterilno vodo za injekcije.
Cubicin (daptomycin) is not physically or chemically compatible with glucose-containing solutions.
Zdravilo Cubicin (daptomicin) fizikalno ali kemijsko ni kompatibilno z raztopinami, ki vsebujejo glukozo.
The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.
Vialo je treba nežno vrteti, da se zagotovi popolna navlažitev celotnega zdravila, in jo nato pustiti, da počiva 10 minut.
Finally the vial should be gently rotated/ swirled for a few minutes as needed to obtain a clear reconstituted solution.
Nazadnje je treba vialo nekaj minut nežno obračati/ vrteti, kolikor je potrebno, da dobimo bistro rekonstituirano raztopino.
The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use.
Rekonstituirano raztopino je treba pazljivo preveriti in se prepričati, da je zdravilo v raztopini, pred uporabo pa je treba vizualno prekontrolirati, da v njej ni vidnih delcev.
The reconstituted solution should then be diluted with sodium chloride intravenous infusion (typical volume 50 ml) and infused over 30 minutes.
Rekonstituirano raztopino je treba nato razredčiti z natrijevim kloridom za intravensko infundiranje (običajni volumen 50 ml) in jo 30 minut infundirati.
Chemical and physical in-use stability on the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours if stored under refrigeration (2 to 8°C).
Kemijska in fizikalna stabilnost rekonstituirane raztopine v viali v času uporabe zdravila je bila dokazana za 12 ur pri 25 °C in do 48 ur, če je bila raztopina shranjena v hladilniku (2 °C - 8 °C).
The combined time (vial and infusion bag) at 25°C should not exceed 12 hours (24 hours if refrigerated).
Skupni čas (v viali in infuzijski vrečki) pri 25 °C ne sme presegati 12 ur (24 ur pri shranjevanju v hladilniku).
Stability of the diluted solution in infusion bags is established as 12 hours at 25°C or 24 hours if stored under refrigeration at 2 to 8°C.
Stabilnost razredčene raztopine v infuzijskih vrečkah je dokazana za 12 ur pri 25 °C ali 24 ur pri shranjevanju v hladilniku pri 2 °C - 8 °C.
If not used immediately, in-use storage times are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless reconstitution / dilution has taken place in controlled and validated aseptic conditions.
Ta čas naj ne bi bil daljši od 24 ur pri 2 do 8 °C, razen če je bila rekonstitucija/ razredčitev izvedena v nadzorovanih in validiranih aseptičnih pogojih.
45 Tell your doctor if you develop any of the following symptoms:
43 Obvestite zdravnika, če pride do katerega od naslednjih simptomov:
46 A course of treatment usually lasts for 1 to 2 weeks for skin infections.
44 Postopek zdravljenja običajno traja od 1 do 2 tednov pri okužbah kože.
49 INFORMATION FOR THE HEALTHCARE PROFESSIONALS
47 INFORMACIJE ZA ZDRAVSTVENE DELAVCE
500 mg presentation: a 50 mg/ ml concentration can be achieved by reconstituting with 10 ml of 0.9% sodium chloride intravenous infusion.
Pakiranje po 500 mg: koncentracijo 50 mg/ ml lahko dosežete z rekonstitucijo s 10 ml 0, 9% natrijevega klorida za intravensko infuzijo.
Vials of 500 mg/ vial can also be reconstituted with sterile water for injections.
Viale s 500 mg/ vialo se lahko rekonstituirajo tudi s sterilno vodo za injekcije.
Cyanokit is a powder to be made up into a solution for infusion (drip into a vein).
Zdravilo Cyanokit je prašek, ki se pripravi v raztopino za infundiranje (dajanje tekočine v veno).
Cyanokit is used as an antidote to treat known or suspected poisoning with cyanide, a highly poisonous chemical.
Zdravilo Cyanokit je protistrup za zdravljenje znane zastrupitve s cianidom ali v primeru suma zastrupitve s cianidom, ki je zelo strupena kemikalija.
Cyanide poisoning usually results from exposure to smoke from fire, from breathing or swallowing cyanide, or from getting it on the skin or mucous membranes (moist body surfaces, such as the lining of the mouth).
Zastrupitev s cianidom je ponavadi posledica izpostavljenosti dimu pri požarih, vdihovanja ali zaužitja cianida ali stika s cianidom prek kože ali sluznice (vlažne površine telesa, npr. v ustih).
It is given as an intravenous infusion over 15 minutes.
Daje se v obliki intravenske infuzije, ki traja 15 minut.
For children, it is 70 mg per kilogram body weight up to a maximum dose of 5 g.
Začetni odmerek za odrasle je 5 g, za otroke pa 70 mg na kilogram telesne mase do največ 5 g.
A second dose can be given, depending on how severe the poisoning is and how well the patient is responding.
Glede na resnost zastrupitve in odziv bolnika se lahko da tudi drugi odmerek.
The second dose is given over a period of between 15 minutes and two hours, depending on the patient’ s condition.
Drugi odmerek se infundira 15 minut do 2 uri, odvisno od stanja bolnika.
The maximum dose is 10 g for adults, and 140 mg/ kg in children up to a maximum of 10 g.
Največji odmerek za odrasle je 10 g, za otroke pa 140 mg/ kg do največ 10 g.
Cyanokit is given along with appropriate measures to decontaminate and support the patient, including providing oxygen for the patient to breathe.
Zdravilo Cyanokit se uporablja skupaj z ustreznimi ukrepi za dekontaminacijo in podporo bolnika, vključno s kisikom za dihanje.
The active substance in Cyanokit, hydroxocobalamin, reacts with cyanide in the body.
Zdravilna učinkovina v zdravilu Cyanokit, hidroksokobalamin, reagira s cianidom v telesu.
This reaction forms cyanocobalamin, a non-poisonous compound that is removed from the body in the urine.
V reakciji nastane cianokobalamin, nestrupena spojina, ki se odstrani iz telesa s sečem.
This lowers cyanide levels in the body and stops the cyanide fixing itself to an enzyme in cells called cytochrome oxidase, which is important for providing energy in cells.
Cianid se ne veže več na celični encim citokrom- oksidazo, ki je pomemben za zagotavljanje energije v celicah.
The effects of Cyanokit were first tested in experimental models before being studied in humans.
Učinki zdravila Cyanokit so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
There have been no studies directly comparing the effectiveness of Cyanokit to any other treatment in humans.
Študij, ki bi neposredno primerjale učinkovitost zdravila Cyanokit s katerim koli drugim zdravilom, pri ljudeh ni bilo.
Information on its effectiveness was obtained in 83 patients who had been admitted to 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Učinkovitost so ugotavljali pri 83 bolnikih, ki so bili sprejeti v bolnišnico s sumom 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged hospital with suspected cyanide poisoning and who received Cyanokit.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged zastrupitve s cianidom in ki so prejeli zdravilo Cyanokit.
A further 14 patients were studied whose cyanide poisoning was due to something other than smoke inhalation; most of these patients had taken cyanide during a suicide attempt.
Preučili so še 14 bolnikov, pri katerih zastrupitev s cianidom ni bila posledica vdihavanja dima; v večini primerov so ti bolniki uporabili cianid pri poskusu samomora.
The information on these patients was obtained from their medical notes, as recorded in databases at two French hospitals.
Podatke o teh bolnikih so pridobili iz zdravniških kartotek, ki so zabeležene v zbirkah podatkov v dveh francoskih bolnišnicah.
In the study of smoke inhalation, the response to Cyanokit was assessed as ‘ positive ’ in 31 patients (45%), ‘ partial’ in 15 (22%) and ‘ absent’ in 10 (15%).
V študiji vdihavanja dima so odziv na zdravilo Cyanokit ocenili pri 31 (45%) bolnikih kot „ pozitiven “, pri 15 (22%) bolnikih kot „ delen “ in pri 19 (15%) bolnikih kot „ odsoten “.
Survival was more likely in those who received Cyanokit before their hearts had stopped, who had less severe symptoms of brain damage and who had lower blood cyanide levels.
Preživetje je bilo bolj verjetno pri bolnikih, ki so prejeli zdravilo Cyanokit, preden se jim je ustavilo srce; pri bolnikih, ki so imeli blažje simptome možganske poškodbe in ki so imeli nižje ravni cianida v krvi.
Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘ lethal’ levels of cyanide in the blood.
Izmed 14 bolnikov, pri katerih zastrupitev s cianidom ni bila posledica vdihavanja dima, jih je 10 preživelo, vključno s sedmimi bolniki, ki so imeli v krvi „ smrtne “ ravni cianida.
Because hydroxocobalamin has an intense red colour, most patients will have dark red discoloration of the skin and mucous membranes for up to 15 days and of the urine for up to 35 days after receiving Cyanokit.
Ker ima hidroksokobalamin intenzivno rdečo barvo, se pri večini bolnikov po prejemu zdravila Cyanokit koža in sluznice obarvajo temno rdeče za do 15 dni, seč pa za do 35 dni.
For the full list of all side effects reported with Cyanokit, see the Package Leaflet.
Za celoten opis neželenih učinkov, o katerih so poročali pri uporabi zdravila Cyanokit, glejte Navodilo za uporabo.
This can be attached to the patient’ s notes so that hospital staff are made aware of these effects of the medicine.
Ta nalepka se lahko nalepi v bolnikovo kartoteko, da je zdravstveno osebje obveščeno o teh učinkih zdravila.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Cyanokit appeared to be a well-tolerated and efficient cyanide antidote, based on its effects on survival and the prevention of brain damage.
Odbor za zdravila za uporabo v humani medicini (CHMP) je glede na to, kako zdravilo vpliva na preživetje in na preprečevanje možganskih poškodb, sklenil, da so bolniki zdravilo Cyanokit dobro prenašali in da se je izkazalo kot učinkovit cianidni protistrup.
There is no information available on success rates with other antidotes for cyanide poisoning, so it was not possible to carry out a comparison between the success rates seen with Cyanokit and with alternatives.
Ker ni podatkov o uspešnosti drugih protistrupov za zastrupitev s cianidom, ni bilo možno primerjati uspešnosti zdravila Cyanokit z alternativnimi protistrupi.
However, the Committee concluded that Cyanokit had advantages over alternative antidotes because it has a good safety profile in patients who have not been poisoned.
Vendar je Odbor mnenja, da ima zdravilo Cyanokit prednosti pred ostalimi protistrupi, ker ima dober varnostni profil pri bolnikih, ki niso bili zastrupljeni.
Therefore, the CHMP decided that Cyanokit’ s benefits are greater than its risks for the treatment of known or suspected cyanide poisoning.
Odbor zato meni, da so koristi zdravila Cyanokit za zdravljenje znane zastrupitve s cianidom ali v primeru suma zastrupitve s cianidom večje od z njim povezanih tveganj.
The Committee recommended that Cyanokit be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Cyanokit.
Other information about Cyanokit:
Druge informacije o zdravilu Cyanokit:
The European Commission granted a marketing authorisation valid throughout the European Union for Cyanokit to Merck Santé s. a. s. on 23 November 2007.
Evropska komisija je dovoljenje za promet z zdravilom Cyanokit, veljavno po vsej Evropski uniji, odobrila družbi Merck Santé s. a. s. dne 23. novembra 2007.
The full EPAR for Cyanokit can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cyanokit je na voljo tukaj.
EU number EU/ 1/ 07/ 420/ 001
Številka EU EU/ 1/ 07/ 420/ 001
Invented name Cyanokit
Izmišljeno ime Cyanokit
Strength 2.5 g
Jakost 2, 5 g
Pharmaceutical form Powder for solution for infusion
Farmacevtska oblika Prašek za raztopino za infundiranje
Route of administration Intravenous use
Pot uporabe Intravenska uporaba
Packaging Vial (glass)
Ovojnina Viala (steklo)
Package size 2 vials + 1 infusion set + 2 transfer devices + 1 short catheter
Velikost pakiranja 2 viali + 1 komplet za infundiranje 2 napravi za prenos + 1 kratek kateter
Cyanokit 2.5 g powder for solution for infusion
Cyanokit 2, 5 g prašek za raztopino za infundiranje
Each vial contains 2.5 g of hydroxocobalamin.
Vsaka viala vsebuje 2, 5 g hidroksokobalamina.
After reconstitution with 100 ml of diluent, each ml of the reconstituted solution contains 25 mg of hydroxocobalamin.
Po rekonstituciji s 100 ml topila vsebuje vsak ml rekonstituirane raztopine 25 mg hidroksokobalamina.
Powder for solution for infusion.
Prašek za raztopino za infundiranje
Treatment of known or suspected cyanide poisoning.
Zdravljenje znane zastrupitve s cianidom ali v primeru suma zastrupitve s cianidom.
Cyanokit is administered as an intravenous infusion over 15 minutes.
Zdravilo Cyanokit se daje v obliki intravenske infuzije, v času 15 minut.
The initial dose of Cyanokit is 5 g.
Začetni odmerek zdravila Cyanokit je 5 g.
In infants to adolescents, the initial dose of Cyanokit is 70 mg/ kg body weight not exceeding 5 g.
Od dojenčkov do mladostnikov je začetni odmerek zdravila Cyanokit 70 mg/ kg telesne mase, vendar odmerek ne sme preseči 5 g.
Body weight in kg Initial dose
Telesna masa v kg Začetni odmerek
Depending upon the severity of the poisoning and the clinical response (see section 4.4), a second dose may be administered by intravenous infusion.
Glede na stopnjo zastrupitve in klinični odziv (glejte poglavje 4. 4) lahko intravensko infundirate naslednji odmerek.
The rate of infusion for the second dose ranges from 15 minutes (for patients extremely unstable) to 2 hours based on patient condition.
Hitrost infundiranja drugega odmerka je od 15 minut (za izjemno nestabilne bolnike) do 2 ur, glede na bolnikovo stanje.
The subsequent dose of Cyanokit is 5 g.
Naslednji odmerek zdravila Cyanokit je 5 g.
In infants to adolescents, the subsequent dose of Cyanokit is 70 mg/ kg body weight not exceeding 5 g.
Od dojenčkov do mladostnikov je naslednji odmerek zdravila Cyanokit 70 mg/ kg telesne mase, vendar odmerek ne sme preseči 5 g.
2 Maximum dose
2 Največji odmerek
The maximum recommended dose is 10 g.
Največji priporočeni odmerek je 10 g.
In infants to adolescents, the maximum recommended dose is 140 mg/ kg not exceeding 10 g.
Od dojenčkov do mladostnikov je največji priporočeni odmerek 140 mg/ kg, vendar ne sme preseči 10 g.
Renal and hepatic impairments Although the safety and efficacy of hydroxocobalamin have not been studied in renal and hepatic impairments, Cyanokit is administered as emergency therapy in an acute, life-threatening situation only and no dosage adjustment is required in these patients.
Okvara ledvic in jeter Čeprav varnosti in učinkovitosti hidroksokobalamina pri bolnikih z okvarami ledvic in jeter niso raziskovali, se zdravilo Cyanokit uporablja samo kot nujno zdravljenje pri akutnih, smrtno nevarnih primerih, pri teh bolnikih pa prilagoditev odmerka ni potrebna.
For instructions on preparation and handling, see section 6.6.
Navodila za pripravo in ravnanje so v poglavju 6. 6.
Treatment decisions must be made on the basis of clinical history and/ or signs and symptoms of cyanide intoxication.
Odločitve o zdravljenju morajo temeljiti na klinični anamnezi in/ ali znakih in simptomih intoksikacije s cianidom.
Common signs and symptoms of cyanide poisoning include: nausea, vomiting, headache, altered mental status (e. g. confusion, disorientation), chest tightness, dyspnoea, tachypnoea or hyperpnoea (early), bradypnoea or apnoea (late), hypertension (early) or hypotension (late), cardiovascular collapse, seizures or coma, mydriasis, and plasma lactate concentration > 8 mmol/ l.
Med pogostimi znaki in simptomi zastrupitve s cianidom so: navzea, bruhanje, glavobol, sprememba duševnega stanja (npr. zmedenost, dezorientiranost), tiščanje v prsnem košu, dispneja, tahipneja ali hiperpneja (zgodaj), bradipneja ali apneja (pozno), hipertenzija (zgodaj) ali hipotenzija (pozno), kardiovaskularni kolaps, epileptični napadi ali koma, midriaza in koncentracija laktata v plazmi > 8 mmol/ l.
The presence of altered mental status (confusion and disorientation) and/ or mydriasis is suggestive of true cyanide poisoning.
Spremenjeno duševno stanje (zmedenost in dezorientiranost) in/ ali midriaza kažeta na resnično zastrupitev s cianidom.
Before Cyanokit is administered, it is recommended to check affected persons for the presence of the following: • exposure to fire smoke in an enclosed area • soot present around mouth, nose and/ or oropharynx • altered mental status
Pred uporabo zdravila Cyanokit je priporočeno pri prizadetih osebah preveriti naslednje: • izpostavljenost dimu zaradi požara v zaprtem prostoru; • prisotnost saj okrog ust, nosa in/ ali orofarinksa; • spremenjeno duševno stanje.
In this setting hypotension and/ or a plasma lactate concentration ≥ 10 mmol/ l (higher than the one mentioned under signs and symptoms due to the fact that carbon monoxide contributes to lactic
3 V teh okoliščinah hipotenzija in/ ali koncentracija laktata v plazmi ≥ 10 mmol/ l (ta vrednost je večja od tiste, ki je navedena med znaki in simptomi, ker ogljikov monoksid prispeva k laktacidemiji) močno kažeta na zastrupitev s cianidom.
Known hypersensitivity to hydroxocobalamin or vitamin B12 must be taken into benefit-risk consideration before administration of Cyanokit, since hypersensitive reactions may occur in patients receiving hydroxocobalamin (see section 4.8).
Znano preobčutljivost za hidroksokobalamin ali vitamin B12 je treba upoštevati pri oceni koristi in tveganja pred uporabo zdravila Cyanokit, saj pri bolnikih, ki prejmejo hidroksokobalamin, lahko pride do preobčutljivostnih reakcij (glejte poglavje 4. 8).
The maximal increase in blood pressure has been observed toward the end of infusion.
Največje zvišanje krvnega tlaka so opazili proti koncu infundiranja.
Because of its deep red colour, hydroxocobalamin has the potential to interfere with determination of laboratory parameters (e. g. clinical chemistry, haematology, coagulation, and urine parameters).
Hidroksokobalamin je temno rdeč, zato lahko moti določanje laboratorijskih parametrov (npr. parametrov klinične kemije, hematologije, koagulacije in urina).
In vitro tests indicate that the extent and duration of the interference is dependant on numerous factors such as the dose of hydroxocobalamin, analyte, analyte concentration, methodology, analyser, concentrations of cobalamins-(III) including cyanocobalamin and partially the time between sampling and measurement.
Preskusi in vitro kažejo, da sta stopnja in trajanje motenja odvisna od številnih dejavnikov, kot so odmerek hidroksokobalamina, analit, koncentracija analita, metodologija, analizator, koncentracije kobalaminov - (III), vključno s cianokobalaminom, ter delno od časa med odvzemom vzorca in meritvijo.
Based on in vitro studies and pharmacokinetic data obtained in healthy volunteers the following table describes interference with laboratory tests that may be observed following a 5 g dose of hydroxocobalamin.
Na podlagi študij in vitro in farmakokinetičnih podatkov, pridobljenih pri zdravih prostovoljcih, naslednja preglednica opisuje interference laboratorijskih testov, ki jih lahko opazimo po 5- gramskem odmerku hidroksokobalamina.
Interference following a 10 g dose can be expected to last up to an additional 24 hours.
Pričakovati je, da bo motenje po 10- gramskem odmerku trajalo do dodatnih 24 ur.
No interference
Trajanje motnje po 5- gramskem Laboratorijski
Duration of
Umetno
Laboratory parameter
parameter
observed
Motnja ni opažena
Artificially increased*
zvišan *
Artificially decreased*
Umetno znižan *
Unpredictable***
Nepredvidljiv ***
interference after a 5 g dose
odmerku
Calcium Sodium Potassium Chloride Urea Gamma glutamyl transferase (GGT)
Kalcij Natrij Kalij Klorid Sečnina Gamaglutamil - transferaza (GGT)
Creatinine Total and conjugate bilirubin** Triglycerides Cholesterol Total protein Glucose Albumin Alkaline
Kreatinin Skupni in konjugirani bilirubin ** Trigliceridi Holesterol Skupne beljakovine Glukoza
Alanine aminotransferase (ALT) Amylase
Alanin - aminotransferaza (ALT) Amilaza
Phosphate Uric acid Aspartate aminotransferase (AST) Creatine kinase (CK) Creatinine kinase isoenzym MB (CKMB) Lactate dehydrogenase
Fosfat Sečna kislina Aspartat - aminotransferaza (AST) Kreatin- kinaza (CK) Kreatinin- kinaza izoencim MB (CKMB)
4
4 Trajanje motnje po 5- gramskem Laboratorijski
No interference
Umetno
Duration of
parameter
Laboratory parameter
Motnja ni opažena
observed
zvišan *
Artificially increased* phosphatase
Umetno znižan *
Artificially decreased*
Nepredvidljiv ***